by CheckRare Staff | Feb 2, 2024
Bill Grambley, CEO of AllazoHealth, explains how his company attacks health inequalities by providing personalized pharmaceutical care with artificial intelligence (AI)-based platforms. AI-based platforms can be utilized to predict patient behavior and...
by CheckRare Staff | Feb 1, 2024
Richard F. Riedel, MD, Medical Oncologist, Duke Health, discusses tyenosynovial giant cell tumors (TGCT), including: – Challenges of diagnosing these rare, benign tumors – Current management strategies – Emerging treatment options – Advice to...
by CheckRare Staff | Feb 1, 2024
Cat Lutz, PhD, MBA, Vice President of the JAX Rare Disease Translational Center, discusses rare disease research’s impact on understanding common diseases. Developing therapeutics for rare diseases come with their own set of unique challenges and...
by CheckRare Staff | Jan 30, 2024
Andy Udell, President of Calliditas Therapeutics North America, discusses current IgA nephropathy treatment options (including Tarpeyo [budesonide]) and the Phase 3 NefIgArd trial. Immunoglobulin A (IgA) nephropathy is a rare, autoimmune, kidney disorder...
by CheckRare Staff | Jan 29, 2024
Hesham Abdullah, MD, MSc, of GSK, discusses myelofibrosis treatment options, including recently approved Ojjaara (momelotinib). Transcription: My name Hesham Abdullah, senior vice president, global head of oncology within R&D at GSK. So I oversee...
